Clicky

BioMarin Pharmaceutical Inc(BM8)

Description: BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.


Keywords: Rare Diseases Virotherapy Orphan Drug Metabolic Disease Lipid Storage Disorders Phenylketonuria Pharmaceutical Wholesalers Enzyme Replacement Therapy Mucopolysaccharidosis Pegylation Biomarin Pharmaceutical Lysosomal Storage Disorder Iduronidase Achondroplasia Naglazyme Severe Hemophilia A Aldurazyme Batten Disease Serious And Life Threatening Rare Diseases Tetrahydrobiopterin

Home Page: www.biomarin.com

770 Lindaro Street
San Rafael, CA 94901
United States
Phone: 415 506 6700


Officers

Name Title
Mr. Alexander Hardy President, CEO & Director
Mr. Brian R. Mueller CPA CFO & Executive VP
Dr. C. Greg Guyer Ph.D. Executive VP & CTO
Dr. Henry J. Fuchs M.D., Ph.D. Advisor
Ms. Erin Burkhart Group VP & Chief Accounting Officer
Dr. Kevin Eggan Ph.D. Chief Scientific Officer & Senior VP of Research and Early Development
Ms. Traci McCarty Group Vice President of Investor Relations
Mr. George Eric Davis J.D. Executive VP, Chief Legal Officer, General Counsel & Secretary
Ms. Humaira Serajuddin Senior VP & Chief Marketing Officer
Ms. Amy Wireman Executive VP & Chief People Officer

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 17.094
Trailing PE: 39.7197
Price-to-Book MRQ: 2.3239
Price-to-Sales TTM: 4.3573
IPO Date:
Fiscal Year End: December
Full Time Employees: 3401
Back to stocks